SGX Market Updates

January STI Gains Take 3-Month Return To 20%


PUBLISHED ON |

01 February 2021

  • The STI added 2.1% in January, taking its 3-month price return to 19.8%, with dividend distributions boosting the 3-month total return to 20.2%. Similarly, the highly correlated FTSE ASEAN All Share Index was comparatively level for January, bringing its 3-month total return to 16.8%.

  • The strongest of the 30 STI stocks in January included Wilmar International, HongKong Land and Thai Beverage. Thai Beverage and Wilmar International were also the STI’s best performers over the past 3 months, with respective returns of 42% and 30%.

  • DBS, OCBC and UOB continued to outpace the top quartile of global banks by market value. The trio averaged 2.2% gains in January, following 3.9% declines in 2020. Combined the 3 banks also led the net institutional inflows of Singapore-listed stocks in January, with S$214 million of inflows.




The Straits Times Index (STI) ended January 2021 at 2902.52, 478.68 points (or 19.8%) higher than the 2423.84 close at the end of October 2020. The 3 months of gains, which saw the onset of retracement on 25 November and then again on 21 January, saw the STI close twice above the key 3000 level. The STI gains coincided with a 16.4% price gain in the regional FTSE ASEAN All-Share Index and a 15.5% price gain for the FTSE Asia Pacific Index. The less correlated, sector-driven S&P 500 Index gained 10.5%.


STI 3-month price returns vs regional indices



STI’s Biggest Driver in Early 2021

The global campaign to overcome the Coronavirus continues to be the biggest driver for the STI. While the STI has declined 3.8% from the 21 January close, Singapore’s most traded medical supply stocks – Medtecs International, Top Glove, Riverstone and UG Healthcare averaged 0.2% gains, bringing their average 3-month decline to 18.1%. The recent 3-month consolidation of the medical supply stocks (note the quartet averaged 600%+ gains for the 6-month ended 31 October) reflects concern on the pace of the vaccine rollouts relative to the prevalence of the contagious strains of the coronavirus.

Two of the global economic powerhouses, the United States and Eurozone currently account for 78% of the global infections recorded by the WHO. Together the United States and the Eurozone account for more than a third of global trade and two-fifths of the global GDP. While the Federal Reserve Balance Sheet has grown 80% since January 2020, with the European Central Bank Balance Sheet up more than 40%, the latter part of January saw global risk markets take on the aforementioned concerns, and price in less optimism in an imminent return to a new normal.

While January saw the price of Gold decline 3.3% in SGD terms, the safe-haven gauge did rebound 5.5% during the final two sessions of the month. With Brent Crude Oil gaining 3.9% during the month, Sembcorp Marine was the Singapore’s most traded non-STI stock in January with 1.4% gains on the month on S$28 million of net institutional inflow.



STI’s Biggest Sector Outpaced Global Peers

The current top quartile of global banks by market value saw a median 0.6% gain in the month of January following median decline of 9.5% in total return over 2020. In Singapore, DBS, OCBC and UOB generated an average gain of 2.2% in January, following average decline of 3.9% in total returns in 2020. Combined the three banks have also led the net institutional inflows of Singapore-listed stocks in January, with S$214 million of inflows recorded (inflows were as high at S$283 million on 21 January).



  • DBS will report its FY20 full year results before market open on 10 Feb (Wednesday).

  • OCBC will report its FY20 full year results before market open on 24 Feb (Wednesday).

  • UOB will report its FY20 full year results before market open on 25 Feb (Thursday).


Key industry drivers going into this year include the ability to expand non-interest income, potential for lower provisions, degree of net interest margin stabilisation, with the broader focus on the potential for an earnings and economic recovery in Singapore.



STI Highlights in January 2021

The STI ended January with a market capitalisation of S$525 billion, representing close to 60% of the combined market capitalisation of all stocks listed on Singapore Exchange.

The strongest of the 30 STI stocks in January included regional plays Wilmar International, HongKong Land and Thai Beverage. 2 of these three stocks, Thai Beverage and Wilmar International were also the STI’s best performers over the past 3 months, with respective returns of 42% and 30%.

The least performing STI stocks in January included City Developments, Keppel Corporation and ComfortDelGro. This brought the average total returns of these 3 stocks over the past 3 months to 15%.

Over the month, STI stocks saw combined net institutional inflows of S$18 million (compared to approximate inflows of S$300 million in January 2020) and combined net retail outflows of S$245 million (compared to approximate outflows of S$130 million in January 2020). Meanwhile, the combined AUM of the SPDR® Straits Times Index ETF and the Nikko AM Singapore STI ETF ended January at S$2.16 billion compared to S$2.07 billion at the end of 2020, with the unit creations and no redemptions generating S$47 million of net inflows into the 2 ETFs.


The recent momentum of the 30 STI stocks is tabled below, with the STI stocks sort by the highest total returns for the past 3 months.

STI Stock SGX
Code
Market
Cap
S$m
Jan 2021
Net
Institutional
Inflow
S$m
Jan 2021
Total Return
%
3-Month
Total Return
%
Sector
Thai Beverage Y92 20,720 7 12.2 42 Consumer Non-Cyclicals
Genting Singapore G13 10,315 -6 0.6 33 Consumer Cyclicals
Wilmar International F34 33,293 51 13.3 30 Consumer Non-Cyclicals
SATS S58 4,311 -10 -3.3 29 Industrials
Jardine Matheson J36 56,544 5 3.8 27 Industrials
CapitaLand C31 16,669 18 -2.1 25 Real Estate (excl. REITs)
CapitaLand Integrated Commercial Trust C38U 13,847 -15 -0.1 25 REITs
DBS D05 64,236 52 0.6 25 Financial Services
UOB U11 39,110 87 3.5 23 Financial Services
Hongkong Land H78 14,372 6 12.8 23 Real Estate (excl. REITs)
OCBC Bank O39 46,170 75 2.6 23 Financial Services
Jardine C&C C07 8,521 42 10.3 21 Consumer Cyclicals
Singapore Airlines C6L 12,186 -18 -4.0 21 Industrials
Mapletree Commercial Trust N2IU 6,862 -12 -2.8 20 REITs
SingTel Z74 38,975 -102 2.2 19 Telecommunications
UOL U14 6,178 -12 -5.1 18 Real Estate (excl. REITs)
ComfortDelGro C52 3,423 -37 -5.4 17 Industrials
Jardine Strategic J37 38,314 2 5.1 17 Industrials
SGX S68 10,605 33 7.5 15 Financial Services
Keppel Corporation BN4 9,106 -9 -6.9 14 Industrials
City Developments C09 6,548 -94 -9.4 14 Real Estate (excl. REITs)
Dairy Farm International D01 7,755 9 4.0 11 Consumer Non-Cyclicals
Ascendas REIT A17U 12,797 -4 3.4 9 REITs
Yangzijiang Shipbuilding BS6 3,791 19 3.1 7 Industrials
ST Engineering S63 11,559 -36 -2.9 6 Industrials
Sembcorp Industries U96 2,939 4 -3.5 4 Utilities
Venture Corporation V03 5,756 9 2.2 3 Technology (Hardware/ Software)
Keppel DC REIT AJBU 4,867 9 6.0 3 REITs
Mapletree Logistics Trust M44U 8,182 -25 -1.5 2 REITs
Mapletree Industrial Trust ME8U 6,747 -29 -0.7 -5 REITs

Source: SGX StockFacts, Refinitiv and Bloomberg (Data as of 29 January 2021)







This article is provided by SGX My Gateway.



SGX My Gateway

SGX's investor education portal with market, product and investment information and events. Sign up now at sgx.com/mygateway to receive our investment updates and economic calendar.

This document is not intended for distribution to, or for use by or to be acted on by any person or entity located in any jurisdiction where such distribution, use or action would be contrary to applicable laws or regulations or would subject Singapore Exchange Limited (“SGX”) to any registration or licensing requirement. This document is not an offer or solicitation to buy or sell, nor financial advice or recommendation for any investment product. This document is for general circulation only. It does not address the specific investment objectives, financial situation or particular needs of any person. Advice should be sought from a financial adviser regarding the suitability of any investment product before investing or adopting any investment strategies. Use of and/or reliance on this document is entirely at the reader’s own risk. Further information on this investment product may be obtained from www.sgx.com. Investment products are subject to significant investment risks, including the possible loss of the principal amount invested. Past performance of investment products is not indicative of their future performance. Examples provided are for illustrative purposes only. While each of SGX and its affiliates (collectively, the SGX Group Companies) have taken reasonable care to ensure the accuracy and completeness of the information provided, each of the SGX Group Companies disclaims any and all guarantees, representations and warranties, expressed or implied, in relation to this document and shall not be responsible or liable (whether under contract, tort (including negligence) or otherwise) for any loss or damage of any kind (whether direct, indirect or consequential losses or other economic loss of any kind, including without limitation loss of profit, loss of reputation and loss of opportunity) suffered or incurred by any person due to any omission, error, inaccuracy, incompleteness, or otherwise, any reliance on such information, or arising from and/or in connection with this document. The information in this document may have been obtained via third party sources and which have not been independently verified by any SGX Group Company. No SGX Group Company endorses or shall be liable for the content of information provided by third parties. The SGX Group Companies may deal in investment products in the usual course of their business, and may be on the opposite side of any trades. SGX is an exempt financial adviser under the Financial Advisers Act (Cap. 110) of Singapore. The information in this document is subject to change without notice. This document shall not be reproduced, republished, uploaded, linked, posted, transmitted, adapted, copied, translated, modified, edited or otherwise displayed or distributed in any manner without SGX’s prior written consent.












Stock / REIT Search

Advertisement

Advertisement